

BOB DOLE
ST DISTRICT, KANSAS

NON HOUSE OFFICE BUILDING
AREA CODE 202
225-2715

COMMITTEES:
AGRICULTURE
GOVERNMENT OPERATIONS

DISTRICT OFFICE:
101 FEDERAL BUILDING
BEAT BEND, KANSAS 67530
AREA CODE 316
SW 3-5423

Congress of the United States
House of Representatives
Washington, D.C. 20515

COUNTIES:		
BARTON	HODGEMAN	RAWLINS
CHEYENNE	JEWELL	REPUBLIC
CLARK	KEARNY	ROOKS
CLOUD	KIOWA	RUSH
DECATUR	LANE	RUSSELL
EDWARDS	LINCOLN	SALINE
ELLIS	LOGAN	SCOTT
ELLSWORTH	MEADE	SEWARD
FINNEY	MITCHELL	SHERIDAN
FORD	MORTON	SHERMAN
GOVE	NESS	SMITH
GRAHAM	NORTON	STAFFORD
GRANT	OSBORNE	STANTON
GRAY	OTTAWA	STEVENS
GREELEY	PAWNEE	THOMAS
HAMILTON	PHILLIPS	TREGO
HASKELL	PRATT	WALLACE
		WICHITA

WASHINGTON, D.C.

FOR RELEASE: A.M. MONDAY, OCTOBER 30, 1967

DOLE ASKS DRUG INQUIRY

Congressman Bob Dole (R-Kans) joined with two other Members of Congress in requesting an investigation of remarks about marijuana allegedly made by Dr. James L. Goddard, Director of the Food and Drug Administration.

Dr. Goddard is reported to have stated that marijuana is no more dangerous than alcohol, and that penalties for possession and use of the drug should be removed.

In a petition to the Chairman of the Intergovernmental Relations Subcommittee of the House Committee on Government Operations, the members expressed "deep concern" over remarks attributed to Dr. Goddard. They also expressed concern over the interpretation or misinterpretation of the Commissioner's remarks, and the resultant consequences.

"Dr. Goddard's remarks might have the effect of encouraging increased usage of the drug in violation of existing law, and at great peril to the health of the Nation," Dole stated upon submission of the petition.

The three Representatives, all members of the Intergovernmental Relations Subcommittee, noted that their Subcommittee has oversight jurisdiction over the Department of Health, Education, and Welfare, and therefore, would have the authority to investigate the remarks, and the effect of those remarks.

"This controversy over the Commissioner's statement necessarily raises the larger issue of the adequacy of federal drug and narcotic control laws, especially the Drug Abuse Control Act and its administration by the Food and Drug Administration, and provides an opportune occasion for a Subcommittee study of this important subject," Dole stated.